New pill VENT-03 aims to calm lupus skin flares

NCT ID NCT07260877

Recruiting now Disease control Sponsor: Ventus Therapeutics U.S., Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tests an experimental tablet called VENT-03 for people with active cutaneous lupus erythematosus (CLE), a condition causing painful skin rashes. Twenty-four adults will take either VENT-03 or a placebo for 4 weeks, then everyone gets VENT-03 for 8 more weeks. Researchers will check if the drug reduces skin inflammation and what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VENT-03 (a tablet)
What this could lead to: If it works, this could point toward a new treatment option for people with cutaneous lupus, reducing skin inflammation and severity.
What could go wrong: This is a very early, small Phase 2a trial with only 24 participants. The drug may not prove effective or safe, and results may not apply to everyone with lupus.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital lobar emphysema cutaneous lupus erythematosus systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLE CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) SLE SLE (SYSTEMIC LUPUS) SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Investigative Site
RECRUITING

Pretoria, South Africa
Investigative Site
RECRUITING

Somerset West, South Africa
Investigative Site
RECRUITING

Badajoz, Spain
Investigative Site
RECRUITING

Madrid, Spain
Investigative Site
RECRUITING

Warsaw, Poland
Investigative Site
RECRUITING

Wroclaw, Poland
Investigative Site
RECRUITING

Durban, South Africa
Investigative Site
RECRUITING

Śląskie, Poland
Investigative Site
RECRUITING

Beverly Hills, California, 90211, United States
Investigative Site
RECRUITING

Clearwater, Florida, 33765, United States
Investigative Site
RECRUITING

DeBary, Florida, 32713, United States
Investigative Site
RECRUITING

Tampa, Florida, 33606, United States
Investigative Site
RECRUITING

Indianapolis, Indiana, 46250, United States
Investigative Site
RECRUITING

Flint, Michigan, 48439, United States
Investigative Site
RECRUITING

Troy, Michigan, 48084, United States
Investigative Site
RECRUITING

Saint Joseph, Missouri, 64506, United States
Investigative Site
RECRUITING

Fairport, New York, 14450, United States
Investigative Site
RECRUITING

Memphis, Tennessee, 38119, United States
Investigative Site
RECRUITING

Allen, Texas, 75013, United States
Investigative Site
RECRUITING

Arlington, Texas, 76012, United States
Investigative Site
RECRUITING

Colleyville, Texas, 76034, United States
Investigative Site
RECRUITING

Haskovo, Bulgaria
Investigative Site
RECRUITING

Plovdiv, Bulgaria
Investigative Site
RECRUITING

Sofia, Bulgaria
Investigative Site
RECRUITING

Paris, France
Investigative Site
RECRUITING

Toulouse, France
Investigative Site
RECRUITING

Tbilisi, Georgia
Investigative Site
RECRUITING

Szeged, Hungary
Investigative Site
RECRUITING

Bialystok, Poland
Investigative Site
RECRUITING

Oświęcim, Poland
Investigative Site
RECRUITING

Poznan, Poland
Investigative Site
RECRUITING

Rzeszów, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.